Bleakley Financial Group LLC Has $298,000 Stake in Edwards Lifesciences Co. (NYSE:EW)

Bleakley Financial Group LLC decreased its position in Edwards Lifesciences Co. (NYSE:EW) by 32.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,521 shares of the medical research company’s stock after selling 2,131 shares during the quarter. Bleakley Financial Group LLC’s holdings in Edwards Lifesciences were worth $298,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Crewe Advisors LLC bought a new position in shares of Edwards Lifesciences in the 1st quarter valued at about $28,000. First Community Trust NA bought a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $29,000. Riverview Trust Co bought a new position in shares of Edwards Lifesciences in the 1st quarter valued at about $34,000. Webster Bank N. A. bought a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $39,000. Finally, Versant Capital Management Inc grew its holdings in shares of Edwards Lifesciences by 206.3% in the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 326 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total transaction of $347,550.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,262,521.36. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,262,521.36. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of the stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 16,250 shares of company stock worth $1,099,238 over the last three months. Insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on EW. Truist Financial decreased their price objective on Edwards Lifesciences from $82.00 to $71.00 and set a “hold” rating for the company in a report on Friday, September 13th. Wells Fargo & Company decreased their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a report on Monday, September 9th. Stifel Nicolaus reduced their price target on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a report on Thursday, July 25th. Daiwa America upgraded Edwards Lifesciences to a “strong-buy” rating in a report on Wednesday, July 31st. Finally, Robert W. Baird cut Edwards Lifesciences from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $102.00 to $70.00 in a report on Thursday, July 25th. Fifteen equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $75.81.

Edwards Lifesciences Stock Up 2.0 %

NYSE EW opened at $70.63 on Thursday. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a 50 day moving average of $68.04 and a 200-day moving average of $78.71. The company has a market cap of $42.56 billion, a price-to-earnings ratio of 30.44, a PEG ratio of 2.83 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The firm had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. During the same period in the prior year, the company earned $0.66 earnings per share. The company’s quarterly revenue was up 6.7% on a year-over-year basis. On average, equities research analysts expect that Edwards Lifesciences Co. will post 2.71 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.